In Situ Formed Z-Scheme Graphdiyne Heterojunction Realizes NIR-Photocatalytic Oxygen Evolution and Selective Radiosensitization for Hypoxic Tumors.
Dongmei WangYou LiaoHaili YanShuang ZhuYunpeng LiuJian LiXue WangXihong GuoZhanjun GuBao-Yun SunPublished in: ACS nano (2022)
Photon radiotherapy is a common tool in the armory against tumors, but it is limited by hypoxia-related radioresistance of tumors and radiotoxicity to normal tissues. Here, we constructed a spatiotemporally controlled synergistic therapy platform based on the heterostructured CuO@Graphdiyne (CuO@GDY) nanocatalyst for simultaneously addressing the two key problems above in radiotherapy. First, the in situ formed Z-scheme CuO@GDY heterojunction performs highly efficient and controlled photocatalytic O 2 evolution upon near-infrared (NIR) laser stimulation for tumor hypoxia alleviation. Subsequently, the CuO@GDY nanocatalyst with X-ray-stimulated Cu + active sites can accelerate Fenton-like catalysis of ·OH production by responding to endogenous H 2 O 2 for the selective killing of tumor cells rather than normal cells. In this way, the sequential combination of NIR-triggered photocatalytic O 2 production and X-ray-accelerated Fenton-like reaction can lead to a comprehensive radiosensitization. Overall, this synergism underscores a controllable and precise therapy modality for simultaneously unlocking the hypoxia and non-selectivity in radiotherapy.
Keyphrases
- visible light
- highly efficient
- early stage
- photodynamic therapy
- locally advanced
- drug release
- radiation induced
- endothelial cells
- radiation therapy
- wastewater treatment
- fluorescence imaging
- high resolution
- induced apoptosis
- fluorescent probe
- gene expression
- dual energy
- cell cycle arrest
- squamous cell carcinoma
- stem cells
- magnetic resonance
- mesenchymal stem cells
- nitric oxide
- oxidative stress
- mass spectrometry
- dna damage response
- high speed
- cell therapy
- single cell
- cell proliferation
- replacement therapy
- pi k akt